AstraZeneca divests Atacand commercial rights to Cheplapharm
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to…
Latest Cardiovascular
-
1 week
-
3 weeks
-
2 months
-
2 months
-
1 week
-
3 weeks
-
2 months
-
2 months